AAA
PDLI

Adams Asset Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Adams Asset Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-86,450
Closed -$689K – 93
2013
Q3 		$689K Hold
86,450
– – 0.12% 75
2013
Q2 		$667K Buy
+86,450
New +$674K 0.1% 74

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Adams Asset Advisors's PDLI Position: Q4 2013 in Review

Adams Asset Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 86,450 shares — an estimated $689K sold.

Adams Asset Advisors first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $689K in Q3 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Adams Asset Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Adams Asset Advisors sold 86,450 PDL BioPharma, Inc. shares in Q4 2013, an estimated $689K.
  • Adams Asset Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Adams Asset Advisors's PDL BioPharma, Inc. position peaked at $689K in Q3 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Adams Asset Advisors's 13F filing for Q4 2013, filed 17 Jan 2014.